The major factors that are expected to hinder growth of the global allergic rhinitis treatment market include the termination of the clinical trial study. For instance, in November 2022, a clinical trial of Tree MATA MPL or Tree MATA immunotherapy for allergic rhinitis and type I hypersensitivity I was terminated due to poor enrollment of subjects. The clinical trial was sponsored by Allergy Therapeutics, a manufacturer of subcutaneous and sublingual immunotherapy treatments.
Market Opportunities – Increasing Launch of Awareness Campaigns
Increasing adoption of inorganic growth strategies such launch of awareness campaigns by key market players is expected to offer lucrative growth opportunities in the market. For instance, in June 2023, Alkem, a global pharmaceutical company, announced that they had launched "Stop Sneeze to Wheeze" Campaign to Raise Awareness on Allergic Rhinitis and Asthma Coexistence during World Allergy Week 2023. The programme highlights the idea of "One Airway, One Disease" and seeks to increase awareness of the coexistence of allergic rhinitis and asthma.
Allergic Rhinitis Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients